Aslan Pharmaceuticals
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 35
- Market Cap
- $1.6M
- Introduction
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company’s major business is research and development and operates only in one single segment.
Clinical Trials
23
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05865041
- Locations
- 🇺🇸
1 Site, Webster, Texas, United States
🇺🇸2 Sites, San Antonio, Texas, United States
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT05694884
- Locations
- 🇨🇦
ASLAN Investigative Site, Toronto, Ontario, Canada
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo ComparatorBiological: ASLAN004
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 302
- Registration Number
- NCT05158023
- Locations
- 🇸🇬
ASLAN Investigative Site, Singapore, Singapore
🇺🇸Tooraj Raoof, MD, Encino, California, United States
🇺🇸Center for Dermatology Clinical Research, Inc., Fremont, California, United States
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT04090229
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, INC, Fremont, California, United States
🇺🇸First OC Dermatology, Los Angeles, California, United States
🇺🇸Direct Helpers Research Center, Miami, Florida, United States
Study of ASLAN004 in Healthy Subjects
- Conditions
- Allergic Disorder
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT03721263
- Locations
- 🇸🇬
CGH Clinical Trials & Research Unit, Singapore, Singapore
- Prev
- 1
- 2
- 3
- 4
- Next